| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Sofosbuvir (JAN/USAN); Sovaldi (TN) | ||||||||
| Abbr | SOF | ||||||||
| Product | SOVALDI (Gilead Sciences) | ||||||||
| Formula | C22H29FN3O9P | ||||||||
| Exact mass | 529.1625 | ||||||||
| Mol weight | 529.4525 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Antiviral DG03198 Anti-HCV agent DG02000 HCV NS5B polymerase inhibitor Transporter substrate DG01665 ABCB1 substrate DG01913 ABCG2 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antiviral, NS5B polymerase inhibitor | ||||||||
| Disease | Chronic hepatitis C virus infection [DS:H00413] | ||||||||
| Target | HCV NS5B polymerase [KO:K22472] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AP Antivirals for treatment of HCV infections J05AP08 Sofosbuvir D10366 Sofosbuvir (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antivirals Anti-hepatitis C (HCV) Agents Sofosbuvir D10366 Sofosbuvir (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D10366 Sofosbuvir (JAN/USAN) Drug groups [BR:br08330] Antiviral DG03198 Anti-HCV agent DG02000 HCV NS5B polymerase inhibitor D10366 Sofosbuvir Transporter substrate DG01665 ABCB1 substrate D10366 Sofosbuvir DG01913 ABCG2 substrate D10366 Sofosbuvir Drug classes [BR:br08332] Antiviral DG03198 Anti-HCV agent D10366 Sofosbuvir Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor HCV NS5A/NS5B inhibitor D10366 Sofosbuvir (JAN/USAN) <JP/US> Antimicrobials abbreviations [BR:br08327] Antivirals Genome replication inhibitor HCV NS5A/NS5B inhibitor D10366 Sofosbuvir (JAN/USAN) New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10366 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10366 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10366 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10366 Drug metabolizing enzymes and transporters [br08309.html] Drug transporters D10366 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D10366 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 36 1 C1a C 9.2183 -16.9828 2 C1c C 10.4121 -17.6720 3 O7a O 11.6059 -16.9828 4 C7a C 12.7996 -17.6720 5 C1c C 13.9933 -16.9828 6 N1b N 15.1872 -17.6720 7 C1a C 10.4121 -19.0502 8 O6a O 12.7996 -19.0504 9 C1a C 13.9933 -15.6045 10 C1y C 20.6947 -17.5762 11 C1y C 21.1222 -18.9240 12 C1z C 22.5361 -18.9339 13 C1y C 22.9826 -17.5921 14 O2x O 21.8444 -16.7531 15 P1b P 16.9323 -16.9828 16 O3b O 15.7425 -16.2958 17 O2b O 18.1300 -16.2913 18 C8y C 18.1320 -14.9154 19 C8x C 19.3096 -14.2375 20 C8x C 19.3114 -12.8591 21 C8x C 18.1186 -12.1683 22 C8x C 16.9410 -12.8461 23 C8x C 16.9392 -14.2245 24 O2b O 18.3120 -17.6964 25 C1b C 19.4866 -16.9441 26 O1a O 20.3166 -20.0168 27 C1a C 23.8864 -19.4877 28 X F 22.1827 -20.1470 29 N4y N 24.2889 -17.1603 30 C8x C 25.4710 -17.8949 31 C8x C 26.6865 -17.2447 32 C8y C 26.7312 -15.8671 33 N4x N 25.5490 -15.1324 34 C8y C 24.3335 -15.7825 35 O5x O 27.9599 -15.2099 36 O5x O 23.1649 -15.0563 BOND 38 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 2 7 1 7 4 8 2 8 5 9 1 #Down 9 10 11 1 10 11 12 1 11 12 13 1 12 13 14 1 13 10 14 1 14 15 16 2 15 15 17 1 16 17 18 1 17 18 19 2 18 19 20 1 19 20 21 2 20 21 22 1 21 22 23 2 22 18 23 1 23 15 24 1 #Down 24 24 25 1 25 10 25 1 #Up 26 11 26 1 #Down 27 12 27 1 #Up 28 12 28 1 #Down 29 13 29 1 #Up 30 29 30 1 31 30 31 2 32 31 32 1 33 32 33 1 34 33 34 1 35 29 34 1 36 32 35 2 37 34 36 2 38 15 6 1 #Up |